Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model

Cancer Biology and Therapy

Volumn 8, Issue 23, 2009, Pages 2237-2245

  Gong, Jing ^a   Yang, David J ^b   Kohanim, Saady ^b   Angelo, Laura S ^a   Kurzrock, Razelle ^a  

^a Division of Cancer Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti phospho tyrosine antibody; EGFR; Gefitinib; Imaging

Indexed keywords

CYSTEINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYLENEDICYSTEINE; GEFITINIB; INDIUM 111; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CARCINOMA CELL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; TREATMENT RESPONSE; TUMOR; XENOGRAFT;

EID: 73949101989     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.23.9986     Document Type: Article

References (50)

1. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Ann Rev Pharamacol Toxicol 2005; 45:357-84.
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65.
3. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15:254-64.
4. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991; 1:72-82.
5. Montemurro F, Balabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007; 2:257-68.
6. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res 2006; 12:7242-51.
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
8. Yang DJ, Kim EE. Tracer development and hybrid imaging. Eur J Med Mol Imaging 2005; 32:1001-2.
9. Merlino GT, Ishii S, Whang-Peng J, Knutsen T, Xu YH, Clark AJ, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 1985; 5:1722-34.
10. Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S, et al. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). Int J Cancer 2007;120:181-8.
11. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (IRESSA). Clin Cancer Res 2002; 8:3496-502.
12. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (IRESSA), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 2001; 94:774-82.
13. Cragg MS, Kuroda J, Puthalakath H, Huang DCS, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Medicine 2007; 4:1681-90.
14. Vermes I, Haanen C, Steffens-Nakken K, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184:39-51.
15. Blondeau P, Berse C, Grave ID. Dimerization of an intermediate during the sodium in liquid ammonia reduction of 1-thiazolidine-4-caroxylic acid. Can J Chem 1967; 45:49-52.
16. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with Tc-99m-L-ethylenedicysteine, a new renal imaging agent. Eur J Nuc Med 1993; 20:738-46.
17. Surma MJ, Wiewiora J, Liniecki J. Usefulness of Tc-99m-N,N-ethylene-1- dicysteine complex for dynamic kidney investigations. Nucl Med Commun 1994; 15:628-35.
18. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 1998; 13:427-35.
19. 99mTc-ethylenedicysteine-colchicine for evaluation of antiangiogenic effects. Anticancer Drugs 1999; 10:685-92.
20. 18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. J Nucl Med 1986; 27:1462-6.
21. 125I]iodo-2′-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting. J Nucl Med 2005; 46:800-6.
22. 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 2006; 47:1153-60.
23. 18F] Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004; 31:1033-41.
24. Rosen MA, Jones RM, Yano Y, Budinger TF. Carbon-11 choline: synthesis, purification and brain uptake inhibition by 2-dimethylaminoethanol. J Nucl Med 1985; 26:1424-8.
25. Ohtsuki K, Akashi K, Aoka Y, Blankenberg FG, Kopiwoda S, Tait JF, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999; 26:1251-8.
26. Saha GB, MacIntyre WJ, Go RT. Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging. Semin Nucl Med 1992; 22:150-61.
27. 99mTc annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998; 116:844-53.
28. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with technetium-99m L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993; 20:738-46.
29. Canet EP, Casalic C, Desenfant A, An MY, Corot C, Obadia JF, et al. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn Reson Med 2000; 43:403-9.
30. Laissy JP, Faraggi M, Lebtahi R, Soyer P, Brillet G, Méry JP, et al. Functional evaluation of normal and ischemic kidney by means of gadolinium-DOTA enhanced TurboFLASH MR imaging: a preliminary comparison with 99Tc-MAG3 dynamic scintigraphy. Magn Reson Imaging 1994; 12:413-9.
31. Kao CH, ChangLai SP, Chieng PU, Yen TC. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma: relation to patient prognosis and chemotherapy response - a preliminary report. Cancer 1998; 83:64-8.
32. Wu HC, Chang CH, Lai MM, Lin CC, Lee CC, Kao A. Using Tc-99m DMSA renal cortex scan to detect renal damage in women with type 2 diabetes. J Diabetes Complications 2003;17:297-300.
33. Blondeau P, Berse C, Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid. Can J Chem 1967; 45:49-52.
34. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937; 59:200-6.
35. 99mTc-EC-guanine: synthesis, biodistribution and tumor imaging in animals. Pharmaceutical Research 2005; 22:1471-9.
36. 99mTc-labeled celebrex. Anti-Cancer Drugs 2004; 15:255-63.
37. 99mTc-metronidazole. Stroke 2003; 34:982-6.
38. 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 2003; 226:465-73.
39. 99mTc- ethylenedicysteine-glucosamine. Cancer Biother Radiopharm 2004; 19:443-58.
40. Hens M, Vaidyanathan G, Welsh P, Zalutsky MR. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 2009; 36:117-28.
41. 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16:73-83.
42. 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002; 17:233-45.
43. 99mTc- ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003; 14:49-56.
44. Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R. Novel in vivo imaging shows upregulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006; 5:2991-3000.
45. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-54.
46. Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T, Yasumoto K. Resistance to gefitinib. Int J Clin Oncol 2006; 11:487-91.
47. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in lung cancer: correlation with clinical response to gefitinib therapy. N Engl J Med 2004; 350:2129-39.
48. 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8:262-77.
49. Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE. Combined radioimmunotherpy and chemotherapy of breast tumor with Y-90-labeled anti-HER2 and anti-CEA antibodies with taxol. Bioconjugate Chem 2005; 16:1117-25.
50. 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm 2003; 18:355-63.